Sharon, Y. and Chu, D.S. (2020) Certolizumab Pegol—Tumor Necrosis Factor Inhibitor for Refractory Uveitis. American Journal of Ophthalmology Case Reports, 18, Article ID: 100633.
https://doi.org/10.1016/j.ajoc.2020.100633

has been cited by the following article:

• TITLE: Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis

  AUTHORS: Yuxuan Liu, Xunyu Zou, Shizhou Cheng, Zuhai Zhang

  KEYWORDS: Non-Infectious Uveitis, Glucocorticoids, Biological Agents

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 7, 2024

  ABSTRACT: One of the main immune-mediated diseases that lead to avoidable blindness is non-infectious uveitis. Glucocorticoids are the first-line therapy choice for noninfectious uveitis; however, biologics are also showing promise in the management of this condition. The description of glucocorticoid and biologic usage in non-infectious uveitis is the main topic of this paper.